Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
The study is testing a new way to treat multiple myeloma, a type of cancer, using a drug called selinexor with three other approved drugs. The goal is to see if this treatment works well for people who are just starting treatment for the cancer.
The study is testing a new way to treat multiple myeloma, a type of cancer, using a drug called selinexor with three other approved drugs. The goal is to see if this treatment works well for people who are just starting treatment for the cancer.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: